The Niche Episode 019 – Biogen, Novo Nordisk, and Merck
Aducanumab skeptics, Novo Nordisk and Merck make acquisitions, but first a market update.
Sponsors
https://www.thescopemethod.com
Story References
https://www.sciencemag.org/news/2020/11/biogen-s-alzheimer-s-drug-candidate-takes-beating-fda-advisers
https://www.merck.com/news/merck-announces-third-quarter-2020-financial-results/
https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=33374
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.